Taysha Gene Therapies presents TSHA-102 Rett data at IRSF 2026
Taysha Gene Therapies will present a suite of clinical and preclinical data on TSHA-102, its intrathecally delivered AAV9 gene therapy for Rett syndrome, at the 2026 International Rett Syndrome Foundation Scientific Meeting in Prior Lake, Minnesota, running from 29 June to 1 July.
The presentations span an oral session, four poster presentations and a company-hosted symposium, covering Phase 1/2 efficacy and safety readouts, natural history analysis, endpoint validation and vector design. The breadth of the programme signals that Taysha is using the specialist meeting to build the scientific and regulatory case for a pivotal trial, not merely to update the rare-disease community.
What the data show
The most consequential dataset comes from the longer-term REVEAL Part A cohort, which enrolled both paediatric and adolescent/adult patients. According to Taysha, functional improvements observed after TSHA-102 administration broadened across multiple domains and continued to deepen through at least twelve months post-dosing, irrespective of the patient's age or baseline disease severity. That durability signal is significant: gene therapies delivered to the central nervous system face questions about the longevity of transgene expression, and data extending beyond six months are relatively sparse in the AAV CNS space.
Alongside the clinical data, the company is presenting a natural history analysis it says demonstrates a clear developmental plateau in Rett syndrome after six years of age. Taysha's interpretation is that this stable period defines a predictable, well-characterised population in which to conduct a single-arm pivotal trial, where a historical comparator is essential to interpreting outcomes without a randomised control arm.
Supporting that design, a separate presentation makes the case for the Rett Syndrome Developmental Milestone Assessment (RS-DMA) as a psychometrically validated primary endpoint that has received FDA backing for single-arm interventional studies. Endpoint selection is one of the more contested issues in rare-disease drug development, and regulatory endorsement of a patient-relevant functional scale would remove a significant uncertainty from Taysha's BLA pathway.
Competitive and regulatory context
TSHA-102 carries Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations from the FDA, as well as Orphan Drug status from the European Commission and an Innovative Licensing and Access Pathway designation from the MHRA. That combination of designations reflects both the severity of the unmet need and the agency's early confidence in the programme, though designations do not guarantee approval.
Rett syndrome affects an estimated 15,000 to 20,000 patients across the US, EU and UK, almost all female, and currently has no approved therapy targeting the underlying MECP2 genetic defect. The field has seen growing interest from gene therapy developers given the monogenic aetiology and the tractability of AAV-mediated CNS delivery. Taysha's use of a self-complementary AAV9 capsid, rather than a single-stranded vector, is argued in its preclinical poster to produce superior MeCP2 expression in the CNS, which the company says supports the rationale for intrathecal administration in TSHA-102.
The mention of a BLA in the company's forward-looking statements section suggests Taysha is at least internally scoping a biologics licence application timeline, though no formal filing date was disclosed. Investors and clinicians will be watching the IRSF presentations for additional safety data, any evidence of dose-response relationships, and clarity on the pivotal trial enrolment schedule, which has not yet been announced publicly.